Prognostický význam amplifikace 1q21 u pacientů s mnohočetným myelomem léčených bortezomibem (Velcade), thalidomidem (Myrin) a konvenční chemoterapií

• Title in English: Prognostic impact of chromosome 1q21 amplification in patients with multiple myeloma treated by bortezomib (Velcade), thalidomide (Myrin) and any conventional therapy
• Authors: NĚMEC Pavel; GREŠLIKOVÁ Henrieta; ZAORALOVÁ Romana; FILKOVÁ Hana; VRANOVÁ Vladimíra; KUPSKÁ Renata; SMEJKALOVÁ Jana; OLTOVÁ Alexandra; KUGLÍK Petr; ADAM Zdeněk; KREJČÍ Marta; POUR Luděk; HÁJEK Roman
• Year of publication: 2007
• Type: Conference abstract
• MU Faculty or unit: Faculty of Medicine
• Description: This study is aimed at comparison of prognostic impact of 1q21 amplification in multiple myeloma patients treated by Veldace, Myrin and conventional therapy. Patients treated with thalidomide based ragimen seem to have trend towards worse prognosis based on overall survival.

Related projects

• Molecular basis of cell and tissue regulations
• University Research Centre - Czech Myeloma Group